Tilray Launches Medical Cannabis in Panama, Expanding Latin American Footprint
TLRY is trading near its 52-week low of $4.2 (5.9% above the low).
Summary
Tilray Medical has commercially launched its first medical cannabis product in Panama, shipping Tilray Oral Solution CBD100 from its EU-GMP-certified facility in Portugal. The product will be distributed through Farmacias Arrocha, one of Panama's leading pharmacy chains, under the country's new medical cannabis framework. This marks a concrete step in Tilray's Latin American expansion, adding a new regulated market to its presence in over 20 countries. The launch follows recent regulatory advancements, including Resolution No. 0406 and the SIUCMAA patient registration system, which create a structured pathway for physician-authorized access. While the immediate revenue impact is likely modest given Panama's market size, the move strengthens Tilray's first-mover advantage in emerging medical cannabis markets and diversifies its international revenue base. The company continues to leverage its Portuguese production hub to supply global demand efficiently.
At the time of this announcement, TLRY was trading at $4.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $526.8M. The 52-week trading range was $4.20 to $23.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.